Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 20/20 | 0.88 |
| ▸ | EGFR | P00533 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | PLK1 | P53350 | 1/20 | 0.71 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.71 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.71 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31613787 | 1.00 | WEE1 (0.88) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL29482710 | 1.00 | WEE1 (0.88) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL21332682 | 1.00 | WEE1 (0.88) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL21332681 | 1.00 | WEE1 (0.88) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL31450832 | 0.94 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL21333309 | 0.94 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL29482704 | 0.94 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL21332688 | 0.94 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL21332940 | 0.94 | WEE1 (1.00) | WEE1EGFRCYP3A4PLK1MAP3K19 | |
| SCHEMBL24221651 | 0.92 | WEE1 (0.75) | WEE1EGFRCYP3A4PLK1MAP3K19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4566612-A2 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Recurium IP Holdings, LLC (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-3762385-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2024-11-28 | — | — | US | disclosed |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | RECURIUM IP HOLDINGS, LLC | 2023-07-06 | — | — | US | disclosed |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | RECURIUM IP HOLDINGS, LLC | 2023-07-06 | — | — | US | disclosed |
| US-20230054854-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2023-02-23 | — | — | US | disclosed |
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | RECURIUM IP HOLDINGS, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | RECURIUM IP HOLDINGS, LLC | 2021-05-13 | — | — | US | disclosed |
| EP-3762385-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Recurium IP Holdings, LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019173082-A1 | SUBSTITUTED L,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Zeno Royalties & Milestones, LLC (US) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019173082-A1 | SUBSTITUTED L,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | Zeno Royalties & Milestones, LLC (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261192-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones | MKI67, BRCA1, CCNI | WEE1 2009/4885EGFR 984/4885CYP3A4 701/4885 |
| US-20210139482-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | WEE1 2009/4885EGFR 984/4885CYP3A4 701/4885 |
| US-20230054854-A1 | COMBINATIONS | WEE2, WEE1, BCL2 | WEE1 2/4885EGFR 955/4885CYP3A4 3724/4885 |
| US-20220024939-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | WEE1 2009/4885EGFR 984/4885CYP3A4 701/4885 |
| US-20240391924-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | MKI67, BRCA1, CCNI | WEE1 2009/4885EGFR 984/4885CYP3A4 701/4885 |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | TP53, BRCA1, MCL1 | WEE1 244/4885EGFR 107/4885CYP3A4 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.